VRP-Clinic Software Evaluation - in Support of Rehabilitation (VRP02)

Not Applicable

Completed

Brief Summary: The current study is designed to evaluate neck movements performed according to the VRP-Clinic software, and to verify that they promote physical activities that correspond with physical rehabilitation.

Detailed Description: The study will take place at Shaare Zedek Medical Center (SZMC). The study will include a single visit.

Each subject will put on the VR headset and perform a series of neck movements guided by graphic instructions appearing in the VR environment. The session will be recorded with a video camera which will subsequently be viewed and evaluated by clinicians. The clinicians will identify each movement seen on the video from a predefined list and determine if such a movement is recommended as part of a rehabilitation training program.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

History of neck related disorders (Whiplash, disc degeneration disease or other acute cervical spine conditions)
Current neck pain
Under medical treatment or observation for any health-related issue during the study
Recent trauma
Oncology background
Acute disease/illness
Pregnancy.
Using drugs that could potentially affect physical function and balance (such as corticosteroids, antipsychotics or antidepressants)
Vision problems that require glasses (not all frame types can fit into the headset)

Arm && Interventions

Group	Intervention	Description
VRP-Clinic	VRP-Clinic	VRP-Clinic software on a virtual reality platform

Primary Outcome Measures

Name	Time	Method
Number of VRP-Clinic Neck Movements That the Assessing Clinician Recognizes as Rehabilitation Movements	Up to 2 weeks after the session	The movements are recorded on video and sent to clinicians for evaluation after the session is completed. The movements are then evaluated by the clinicians according to a predetermined list.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Any Adverse Event Occurring During the Study	through study completion, an average of 2 weeks	Safety measure - The number of participants with any adverse event reported by the subject or observed by the investigator/clinician during the study will be recorded.